Search This Blog

Wednesday, June 24, 2009

BESIVANCE, A NEW TOPICAL FLUOROQUINILONE


Besivance is besifloxacin ophthalmic suspension, 0.6%. It prolongs the ocular survface residency time and therefore likely enhances therapeutic efficacy.

No comments:

Post a Comment

Leave a Comment or Question: